Russian Scientists Develop Drug Repurposing Method to Find New Uses for Existing Medicines

Researchers at Sechenov University in Russia are developing a drug repurposing methodology — an approach that identifies new targets in the body for well-known molecules whose safety has already been established. To do this, they use molecular docking, a computer modelling technique that predicts whether a substance can bind to a receptor and how strong that interaction would be.

Three such drugs are currently being studied at the university's Neulybin Institute of Pharmacy and may receive new medical indications in the future. One drug, currently used in cardiology, is being tested for coloproctology — to treat anorectal fissures and promote wound healing after haemorrhoid removal. A second cardiology drug is being proposed as an antispasmodic for gum treatment, while a third compound originally intended for endocrine disorders is being recommended for atopic dermatitis.

Each new use may require a change in formulation: instead of tablets, the scientists are creating gels and creams better suited for topical application. To improve the solubility and bioavailability of the active ingredients, they are using solid dispersion technology with polymer matrices.

The next phase will involve clinical trials of the three repurposed drugs with volunteer participants, with one planned to move to Sechenov University's Clinic of Coloproctology and Minimally Invasive Surgery. After the trials are completed, the drugs must be registered through the established procedure before they can be used in clinical practice; timelines for the trials and registration have not been specified.

Drug repurposing is a recognised global trend. The US Food and Drug Administration recently launched an initiative to find new treatments for severe and rare diseases by leveraging existing safety data to bring drugs to new patient populations more quickly.